Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNTO 328 plus best supportive care versus placebo plus best supportive care in multicentric Castleman disease
NL-OMON36768Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of siltuximab in multicentric angiofollicular lymphoid hyperplasia (MCD), sponsored by Janssen Pharmaceutical. Started May 2010; status: active, not recruiting.
02
Drugs
siltuximab
03
Conditions
multicentric angiofollicular lymphoid hyperplasia (MCD)
Beyond the preview
Go deeper on NL-OMON36768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36768.